Phase 2 N=57 Efficacy and Tolerability of an Intra-Nasal Testosterone Product
Hypogonadism
Primary: Serum Testosterone Ln-Cmax — 6.25; 6.41; 6.54; 6.36 ng/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
Healthy Volunteers
Primary: Efficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity — -3.57; -70.80; -60.83; -69.85 Percent change…
Phase 2 N=110 Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults
Tuberculosis
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 38; 40; 9; 1 Participants
Phase 2 N=253 Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder
Female Orgasmic Disorder
Primary: Number of Orgasms Over an 84 Day Period Compared to Placebo Over the Entire Treatment Period — 2.8; 3.9; 3.2; 1.9 orgasms
Phase 2 N=206 Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis
Cellulitis
Primary: The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid. — 6; 4 Participants
Phase 2 N=177 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease
Primary: Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3 — -2.46; -2.55; -1.17; 0.09 Percentage change — p=0.0127
Phase 2 N=50 Treatment of Traumatic Brain Injury With Hyperbaric Oxygen Therapy
Brain Injury, Chronic
Primary: Computer Cognitive Test Scores - ImPACT Verbal Memory — 70.48; 74.21; 78.12; 75.36 units on a scale
Phase 2 N=240 Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Kaplan Meier Estimate of Progression-Free Survival (PFS) as Assessed by the Investigator — 3.2; 4.5; 4.2 months
Phase 2 N=54 Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
Healthy Volunteers
Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration — -7.06; -67.79; -78.51; -95.04 Percent change in…
Phase 2 N=18 A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002
Phase 2 N=110 Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
Adult Primary Liver Cancer · Hepatitis C Infection
Primary: Change in Serum AFP Levels — -1.928; 5.855 ng/mL — p=0.160
Phase 2 N=64 A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children
Hematologic Diseases · Neoplasms
Primary: Dose of Remifentanil Required to Prevent Movement in Response to Lumbar Puncture Needle Insertion — 0.96; 0.28; 1.50; 0.52 micrograms/kg
Phase 2 N=29 Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Recurrent Salivary Gland Cancer · Stage IVA Salivary Gland Cancer · Stage IVB Salivary Gland Cancer
Primary: Response Rate — 1; 2; 23; 3 Participants
Phase 2 N=109 Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF) — -23.3; -74.0 percent change
Phase 2 N=83 Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).
Complicated Intra-abdominal Infections
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 52.5; 59.1; 8.2; 4.5 percentage of participants